7-Fluoro-4,5-dihydro-3H-spiro[benzo[b][1,4]oxazepine-2,4'-piperidine]

Catalog No.: 
ACTORO431
CAS No.: 
1956331-89-7
Molecular Formula: 
C13H17FN2O
Molecular Weight: 
236.29
7-Fluoro-4,5-dihydro-3H-spiro[benzo[b][1,4]oxazepine-2,4'-piperidine] structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$296.00InquiryInquiry
1g97%$903.00InquiryInquiry
5g97%$4470.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7-Fluoro-4,5-dihydro-3H-spiro[benzo[b][1,4]oxazepine-2,4'-piperidine]
IUPAC Name7-fluoro-4,5-dihydro-3H-spiro[benzo[b][1,4]oxazepine-2,4'-piperidine]
MDL No.MFCD27922464
Molecular FormulaC13H17FN2O
Molecular Weight236.29
SMILESFC1=CC=C2OC3(CCNCC3)CCNC2=C1
InChI KeyQUJUWQPTZDRWQG-UHFFFAOYSA-N
Synonym7-FLUORO-4,5-DIHYDRO-3H-SPIRO[BENZO[B][1,4]OXAZEPINE-2,4-PIPERIDINE];Spiro[1,5-benzoxazepine-2(3H),4'-piperidine], 7-fluoro-4,5-dihydro-
CAS No.1956331-89-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACTORO431 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTORO431 route product structure diagram
    ACTORO4311956331-89-7
Inquiry

2. ACTORO431 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTORO431 route product structure diagram
    ACTORO4311956331-89-7
Inquiry

3. ACTORO431 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTORO431 route product structure diagram
    ACTORO4311956331-89-7
Inquiry

Comments (0)